Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

GeoVax Labs, Inc. - Common Stock (NQ:GOVX)

0.3980 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Dec 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1
Open 0.3980
Bid (Size) 0.3880 (500)
Ask (Size) 0.4199 (5,200)
Prev. Close 0.3980
Today's Range 0.3980 - 0.3980
52wk Range 0.3650 - 2.710
Shares Outstanding 2,172,309
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
GeoVax Announces Issuance of U.S. Patent Covering Enhanced Therapeutic Use of Gedeptin(R) Gene Therapy
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Intellectual Property
GeoVax Announces Issuance of U.S. Patent Covering Enhanced Therapeutic Use of Gedeptin(R) Gene Therapy
Via TheNewswire.com
Topics Intellectual Property

Performance

YTD
-84.0%
-84.0%
1 Month
-20.5%
-20.5%
3 Month
-42.2%
-42.2%
6 Month
-67.4%
-67.4%
1 Year
-84.7%
-84.7%

More News

Read More
GeoVax Announces JCO Oncology Advances Publication Highlighting Favorable Safety and Evidence of Disease Stability of Gedeptin(R) in Recurrent Head & Neck Cancer
Via TheNewswire.com
Topics Death
News headline image
GeoVax Announces JCO Oncology Advances Publication Highlighting Favorable Safety and Evidence of Disease Stability of Gedeptin(R) in Recurrent Head & Neck Cancer
Via NewMediaWire
Topics Death
GeoVax to Present at the Noble Capital Markets Twenty-First Annual Emerging Growth Equity Conference
Via TheNewswire.com
GeoVax Recognizes World Immunization Day: Advancing Innovation and Trust in Vaccination
Via TheNewswire.com
Topics Death
GeoVax Announces Relocation of Corporate Headquarters and Laboratory Operations to Support Accelerated Growth and Pipeline Advancement
Via TheNewswire.com
GeoVax Welcomes New IDSA Guidance Highlighting Need for Tailored COVID-19 Vaccines for Immunocompromised Patients
Via TheNewswire.com
News headline image
GeoVax to Present at the Noble Capital Markets Twenty-First Annual Emerging Growth Equity Conference
Via NewMediaWire
News headline image
GeoVax Reports Third Quarter 2025 Financial Results and Provides Business Update
Via NewMediaWire
GeoVax Reports Third Quarter 2025 Financial Results and Provides Business Update
Via TheNewswire.com
News headline image
GeoVax Recognizes World Immunization Day: Advancing Innovation and Trust in Vaccination
Via NewMediaWire
Topics Death
News headline image
GeoVax to Report Third Quarter 2025 Financial Results and Provide Corporate Update on November 13, 2025
Via NewMediaWire
GeoVax to Report Third Quarter 2025 Financial Results and Provide Corporate Update on November 13, 2025
Via TheNewswire.com
News headline image
GeoVax Announces Relocation of Corporate Headquarters and Laboratory Operations to Support Accelerated Growth and Pipeline Advancement
Via NewMediaWire
BIO CEO Warns U.S. Could Lose Biotech Leadership Within Two Years; GeoVax Calls on Congress and Administration to Act Now
Via TheNewswire.com
Topics Supply Chain
News headline image
BIO CEO Warns U.S. Could Lose Biotech Leadership Within Two Years; GeoVax Calls on Congress and Administration to Act Now
Via NewMediaWire
Topics Supply Chain
News headline image
GeoVax Connects IDSA Guidance on COVID-19 Vaccination for Immunocompromised Patients With Recent Clinical Data for GEO-CM04S1
Via NewMediaWire
GeoVax Connects IDSA Guidance on COVID-19 Vaccination for Immunocompromised Patients With Recent Clinical Data for GEO-CM04S1
Via TheNewswire.com
News headline image
GeoVax Welcomes New IDSA Guidance Highlighting Need for Tailored COVID-19 Vaccines for Immunocompromised Patients
Via NewMediaWire
News headline image
GeoVax Highlights Urgent Need for Multisource Mpox Vaccine Supply Following California Clade 1 Cases
Via NewMediaWire
Topics Economy
GeoVax Highlights Urgent Need for Multisource Mpox Vaccine Supply Following California Clade 1 Cases
Via TheNewswire.com
Topics Economy
GeoVax Highlights Positive Interim Results for Multi-Antigen COVID-19 Vaccine in Immunocompromised Patients at World Vaccine Congress Europe 2025
Via TheNewswire.com
News headline image
GeoVax Highlights Positive Interim Results for Multi-Antigen COVID-19 Vaccine in Immunocompromised Patients at World Vaccine Congress Europe 2025
Via NewMediaWire
News headline image
GeoVax Leadership to Participate in Key European Meetings to Advance Partnering Discussions
Via NewMediaWire

Frequently Asked Questions

Is GeoVax Labs, Inc. - Common Stock publicly traded?
Yes, GeoVax Labs, Inc. - Common Stock is publicly traded.
What exchange does GeoVax Labs, Inc. - Common Stock trade on?
GeoVax Labs, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for GeoVax Labs, Inc. - Common Stock?
The ticker symbol for GeoVax Labs, Inc. - Common Stock is GOVX on the Nasdaq Stock Market
What is the current price of GeoVax Labs, Inc. - Common Stock?
The current price of GeoVax Labs, Inc. - Common Stock is 0.3980
When was GeoVax Labs, Inc. - Common Stock last traded?
The last trade of GeoVax Labs, Inc. - Common Stock was at 12/09/25 04:00 PM ET
What is the market capitalization of GeoVax Labs, Inc. - Common Stock?
The market capitalization of GeoVax Labs, Inc. - Common Stock is 864.58K
How many shares of GeoVax Labs, Inc. - Common Stock are outstanding?
GeoVax Labs, Inc. - Common Stock has 865K shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.